These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 9787732)

  • 41. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sibutramine produces dose-related weight loss.
    Bray GA; Blackburn GL; Ferguson JM; Greenway FL; Jain AK; Mendel CM; Mendels J; Ryan DH; Schwartz SL; Scheinbaum ML; Seaton TB
    Obes Res; 1999 Mar; 7(2):189-98. PubMed ID: 10102256
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological management of obesity.
    Hanif MW; Kumar S
    Expert Opin Pharmacother; 2002 Dec; 3(12):1711-8. PubMed ID: 12472368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacotherapy of obesity.
    Finer N
    Best Pract Res Clin Endocrinol Metab; 2002 Dec; 16(4):717-42. PubMed ID: 12468417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [What is the role of drugs in therapy of obesity?].
    Schusdziarra V
    Wien Med Wochenschr; 1998; 148(17):401-2. PubMed ID: 9887502
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A one-year trial to assess the value of orlistat in the management of obesity.
    James WP; Avenell A; Broom J; Whitehead J
    Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.
    Coutinho W
    Arq Bras Endocrinol Metabol; 2009 Mar; 53(2):262-70. PubMed ID: 19466219
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of Pediatric Obesity: An Umbrella Systematic Review.
    Rajjo T; Mohammed K; Alsawas M; Ahmed AT; Farah W; Asi N; Almasri J; Prokop LJ; Murad MH
    J Clin Endocrinol Metab; 2017 Mar; 102(3):763-775. PubMed ID: 28359101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sibutramine. A review of its contribution to the management of obesity.
    McNeely W; Goa KL
    Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
    JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
    Viner RM; Hsia Y; Tomsic T; Wong IC
    Obes Rev; 2010 Aug; 11(8):593-602. PubMed ID: 19922432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM; Huang BY; Fanchiang JK; Chen CH
    Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Anti-obesity drugs: sibutramine and orlistat].
    Sempere I Verdú E; Palop Larrea V; Hidalgo Mora JJ; Martínez-Mir I
    Med Clin (Barc); 2002 Mar; 118(11):437; author reply 437-8. PubMed ID: 11943108
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety.
    Glazer G
    Arch Intern Med; 2001 Aug 13-27; 161(15):1814-24. PubMed ID: 11493122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Orlistat, a new lipase inhibitor for the management of obesity.
    Heck AM; Yanovski JA; Calis KA
    Pharmacotherapy; 2000 Mar; 20(3):270-9. PubMed ID: 10730683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sibutramine--a review of clinical efficacy.
    Lean ME
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S30-6; discussion 37-9. PubMed ID: 9130039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current concepts in the pharmacological management of obesity.
    Carek PJ; Dickerson LM
    Drugs; 1999 Jun; 57(6):883-904. PubMed ID: 10400403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacologic agents for the treatment of obesity.
    Mathys M
    Clin Geriatr Med; 2005 Nov; 21(4):735-46, vii. PubMed ID: 16182086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.